Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas

Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors

(2018) Anthony W. Tolcher et al.   MOLECULAR CANCER THERAPEUTICS

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer

(2016) D. Oddo et al.   CANCER RESEARCH

The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma

(2016) Alex Kim et al.   Expert Opinion on Drug Discovery

EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E–Mutant NSCLC Cell Lines

(2016) Sung-Moo Kim et al.   MOLECULAR CANCER THERAPEUTICS

Pediatric Sarcomas

(2016) Regan F. Williams et al.   SURGICAL CLINICS OF NORTH AMERICA

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate

(2016) Penella Woll   Therapeutics and Clinical Risk Management

BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment

(2015) Svetlana A. Protsenko et al.   INVESTIGATIONAL NEW DRUGS

Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression

(2015) B. A. Teicher et al.   MOLECULAR CANCER THERAPEUTICS

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

(2015) David M. Hyman et al.   NEW ENGLAND JOURNAL OF MEDICINE

BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies

(2015) Francesco Spagnolo et al.   OncoTargets and Therapy

Genomic landscape of liposarcoma

(2015) Deepika Kanojia et al.   Oncotarget

BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance

(2015) Gerald S. Falchook et al.   Oncotarget

Novel Secondary Somatic Mutations in Ewing's Sarcoma and Desmoplastic Small Round Cell Tumors

(2014) Yunyun Jiang et al.   PLoS One

Two cases of clear cell sarcoma with different clinical and genetic features: cutaneous type withBRAFmutation and subcutaneous type withKITmutation

(2013) B.M. Park et al.   BRITISH JOURNAL OF DERMATOLOGY

Resistance to BRAF-targeted therapy in melanoma

(2013) Ryan J. Sullivan et al.   EUROPEAN JOURNAL OF CANCER

Growth rate of late passage sarcoma cells is independent of epigenetic events but dependent on the amount of chromosomal aberrations

(2013) Mustafa Becerikli et al.   EXPERIMENTAL CELL RESEARCH

A STATement on Vemurafenib-Resistant Melanoma

(2013) Edward J. Hartsough et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma

(2012) Vipin Yadav et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The role of BRAF V600 mutation in melanoma

(2012) Paolo A Ascierto et al.   Journal of Translational Medicine

Vemurafenib: the first drug approved for BRAF-mutant cancer

(2012) Gideon Bollag et al.   NATURE REVIEWS DRUG DISCOVERY

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

(2012) Ryan B. Corcoran et al.   Cancer Discovery

Resistance to BRAF Inhibitors: Unraveling Mechanisms and Future Treatment Options

(2011) J. Villanueva et al.   CANCER RESEARCH

High-resolution genomic mapping reveals consistent amplification of the fibroblast growth factor receptor substrate 2 gene in well-differentiated and dedifferentiated liposarcoma

(2011) Xiaoke Wang et al.   GENES CHROMOSOMES & CANCER

Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling

(2011) Nikhil Wagle et al.   JOURNAL OF CLINICAL ONCOLOGY

Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases

(2011) M. Cargnello et al.   MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas

(2010) John T. Lee et al.   Pigment Cell & Melanoma Research

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

(2010) E. W. Joseph et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA